Discover
SNDX
Syndax Pharmaceuticals, Inc.
20.89
2 x 15.75
2 x 26.84
bid
ask
-
0.97
4.44%
2 @ 04:00 PM
20.51 -0.38 (1.84%)
| Ytd | -0.57% | |
| 1y | 136.85% |
20.70
day range
22.29
8.59
52 week range
25.59
| Open | 22.02 | Prev Close | 21.86 | Low | 20.70 | High | 22.29 | Mkt Cap | 1.85B |
| Vol | 2.14M | Avg Vol | 1.84M | EPS | -2.79 | P/E | N/A | Forward P/E | -41.79 |
| Beta | 0.39 | Short Ratio | 11.70 | Inst. Own | 116.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 19.87 | 200-d Avg | 19.67 | 1yr Est | 39.00 |
SNDX News
globenewswire.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
benzinga.com
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SND
benzinga.com
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 Congr
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or K
benzinga.com
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabin
– High response rates observed with the all-oral combination in a heavily pretreated population, inc
benzinga.com
Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Tr
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resume
benzinga.com
Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including
Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovat